# TOFAcitinib in SARS-CoV2 Pneumonia

> **NCT04332042** · PHASE2 · UNKNOWN · sponsor: **Università Politecnica delle Marche** · enrollment: 50 (estimated)

## Conditions studied

- SARS-COv2 Related Interstitial Pneumonia

## Interventions

- **DRUG:** Tofacitinib

## Key facts

- **NCT ID:** NCT04332042
- **Lead sponsor:** Università Politecnica delle Marche
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-10
- **Primary completion:** 2020-06-20
- **Final completion:** 2020-07-10
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2020-04-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04332042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04332042, "TOFAcitinib in SARS-CoV2 Pneumonia". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT04332042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*